Mereo Biopharma Group Plc

Mereo Biopharma Group Plc is a London-based biopharmaceutical company focused on developing treatments for cancer and rare diseases. Its portfolio includes etigilimab, an innovative therapy in trials for tumor treatment, and Navicixizumab for late-stage ovarian cancer. Other notable projects involve therapies for chronic obstructive pulmonary disease and hypogonadotropic hypogonadism, alongside rare disease treatments like Setrusumab for osteogenesis imperfecta. Mereo collaborates with notable institutions like The University of Texas MD Anderson Cancer Center and has licensing agreements to advance its research and potential commercialization efforts.